PTSD: PMHNP Board Review

Post-traumatic stress disorder (PTSD) develops after exposure to actual or threatened death, serious injury, or sexual violence, and is defined by four symptom clusters — intrusion, avoidance, negative alterations in cognition/mood, and alterations in arousal/reactivity — persisting for more than 1 month. The single highest-yield board point: first-line treatment is an SSRI or SNRI plus trauma-focused psychotherapy, and benzodiazepines are to be avoided because they worsen outcomes and do not treat core PTSD symptoms.

This review organizes the four clusters, the treatment hierarchy, and the management traps the exam targets.

Epidemiology and course

Lifetime PTSD prevalence is roughly 6–8%, about twice as high in women, though the trauma types differ (interpersonal/sexual violence in women; combat and accidents in men). Most people exposed to trauma do not develop PTSD, so individual vulnerability and recovery factors matter: prior trauma, pre-existing psychiatric illness, lack of social support, peritraumatic dissociation, and the severity and interpersonal nature of the event all raise risk, while strong social support is protective. The course varies — many patients recover within months, but a substantial minority follow a chronic, relapsing course. Comorbidity is the rule rather than the exception: depression, substance use disorders, other anxiety disorders, and increased suicide risk frequently accompany PTSD and should be screened for at every visit.

Diagnostic criteria (DSM-5-TR)

Criterion A — Exposure: direct experience, witnessing, learning of an event that happened to a close family member or friend (per DSM-5-TR, when that event is a death, it must have been violent or accidental), or repeated/extreme indirect exposure (e.g., first responders) to actual or threatened death, serious injury, or sexual violence.

Then at least one symptom from the intrusion and avoidance clusters and two from each of the remaining clusters:

• Intrusion (≥1): distressing memories, nightmares, flashbacks, intense distress or physiologic reactivity to cues.
• Avoidance (≥1): avoiding trauma-related thoughts/feelings or external reminders (people, places, situations).
• Negative alterations in cognition and mood (≥2): amnesia for the event, persistent negative beliefs, distorted blame, persistent negative emotional state, anhedonia, detachment, inability to feel positive emotions.
• Alterations in arousal and reactivity (≥2): irritability/aggression, reckless or self-destructive behavior, hypervigilance, exaggerated startle, concentration problems, sleep disturbance.

Duration and impact: symptoms last more than 1 month and cause significant distress or impairment; not due to a substance or medical condition.

Specifiers: with dissociative symptoms (depersonalization/derealization) and with delayed expression (full criteria not met until ≥6 months after the trauma).

DSM-5 (2013) moved PTSD out of the anxiety disorders into the trauma- and stressor-related disorders chapter, and DSM-5-TR retains that placement — a frequently tested classification point. The same chapter includes acute stress disorder, adjustment disorders, and the childhood attachment disorders (reactive attachment disorder and disinhibited social engagement disorder). There is also a separate symptom set for PTSD in children 6 years and younger, which is developmentally adjusted (for example, trauma themes expressed in play).

Acute stress disorder vs. PTSD — the duration line

• Acute stress disorder (ASD): trauma-related symptoms lasting 3 days to 1 month after exposure.
• PTSD: symptoms persisting more than 1 month.

This 1-month boundary is the classic distinguishing exam point.

Clinical features and differential

PTSD frequently co-occurs with depression, substance use disorders, and other anxiety disorders. Consider:

• Adjustment disorder: the stressor need not be life-threatening, and the full PTSD symptom profile is absent.
• Acute stress disorder: same symptoms, shorter duration.
• Major depressive disorder: overlapping anhedonia and negative mood, but lacks the trauma-linked intrusion and avoidance — see the MDD review.
• Panic disorder and GAD: anxiety not anchored to a traumatic event — see the GAD vs. panic review.
• Complex trauma presentations may overlap with emotion-dysregulation pictures like borderline personality disorder (see the BPD review).
• Dissociative disorders, traumatic brain injury, and psychotic disorders can mimic specific PTSD features; flashbacks (reliving) are distinct from hallucinations (perceptions without a stimulus), a distinction the boards may probe.

A frequently tested nuance: PTSD requires that the symptoms follow the traumatic exposure and are linked to it. Pre-existing, unrelated anxiety or mood symptoms do not become PTSD simply because a trauma later occurred. The intrusion and avoidance clusters specifically tie the disturbance back to the index trauma, which is what separates PTSD from generalized anxiety, depression, or an adjustment disorder.

First-line treatment

Psychotherapy

Trauma-focused psychotherapy is first-line and, for many patients, preferred over medication. The evidence-based modalities:

• Cognitive processing therapy (CPT)
• Prolonged exposure (PE) therapy
• Trauma-focused CBT
• Eye movement desensitization and reprocessing (EMDR)

The board pattern is that trauma-focused, exposure-based therapies that directly process the traumatic memory carry the strongest evidence and are preferred when available and tolerated. They work by reducing avoidance and correcting trauma-related beliefs, breaking the cycle that maintains the disorder. Stabilization, psychoeducation, and skills for managing arousal often precede formal exposure work in patients who are highly dysregulated.

Pharmacotherapy

SSRIs and SNRIs are first-line medications. Sertraline and paroxetine are FDA-approved for PTSD; venlafaxine (SNRI) also has strong evidence.

• Allow 4–6 weeks (often longer in PTSD) for response; see the SSRI exam review and PMHNP psychopharmacology high-yield.
• Combination of medication plus trauma-focused therapy is often used for moderate-to-severe PTSD.
• Continue an effective medication for at least 6–12 months before considering a slow taper; PTSD relapse is common.

When first-line SSRIs/SNRIs are insufficient, switching within or between classes is reasonable. Evidence does not support routine adjunctive antipsychotics, and there is concern that early use of medication should never displace access to trauma-focused psychotherapy, which carries the most durable benefit.

Prazosin for nightmares

Prazosin, an alpha-1 adrenergic antagonist, specifically targets trauma-related nightmares and sleep disturbance. It is the go-to exam answer when a PTSD patient's chief complaint is recurrent nightmares. Monitor for orthostatic hypotension and titrate from a low bedtime dose. Although clinical trial results have been mixed, prazosin remains the most commonly tested and widely used pharmacologic option specifically for PTSD nightmares, and it does not carry dependence risk.

Early-intervention caution

A tested point: routine debriefing immediately after a trauma (single-session critical incident stress debriefing) is not recommended and may even be harmful. The evidence-based early intervention is watchful waiting with support, and trauma-focused CBT for those who develop persistent symptoms.

What to avoid

• Benzodiazepines: avoid. They do not treat core PTSD symptoms, may impair extinction learning from exposure therapy, worsen long-term outcomes, and carry dependence risk — especially given high comorbid substance use. This is a heavily tested point.
• Routine antipsychotics are not first-line; reserve adjunctive use for specific refractory or psychotic presentations.

High-yield board pearls

• The four clusters are intrusion, avoidance, negative cognition/mood, and arousal/reactivity, lasting more than 1 month.
• Acute stress disorder is the same picture lasting 3 days to 1 month; PTSD is beyond 1 month.
• Sertraline and paroxetine are FDA-approved for PTSD; SSRIs/SNRIs are first-line pharmacotherapy.
• Trauma-focused psychotherapy (CPT, PE, EMDR) is first-line and often preferred over medication.
• Prazosin is the targeted treatment for PTSD nightmares.
• Avoid benzodiazepines — they worsen outcomes and impair exposure-based therapy.

Common exam traps

• Prescribing a benzodiazepine for PTSD-related anxiety or insomnia. This is the most common trap — the answer is to avoid them.
• Diagnosing PTSD before 1 month. Under a month it is acute stress disorder.
• Forgetting Criterion A. The stressor must involve actual or threatened death, serious injury, or sexual violence; an ordinary life stressor points to adjustment disorder.
• Overlooking prazosin when the stem emphasizes nightmares.
• Choosing an antipsychotic first-line. SSRIs/SNRIs and trauma-focused therapy come first.
• Expecting rapid medication response — PTSD often needs a longer trial than uncomplicated depression.

Clinical decisions should follow current guidelines and individualized assessment; this material is educational.

Practice PTSD questions on PASSNP

The benzodiazepine-avoidance rule and the prazosin-for-nightmares pearl are reliable PMHNP exam points. PASSNP's verified question bank drills the clusters and treatment hierarchy with full rationales. Take a free diagnostic assessment, explore the PMHNP question bank, or register for free to start practicing trauma-disorder items today.